Skip to main content
Company profile
CRISPR Therapeutics AG - logo

CRISPR Therapeutics AG -

Pipeline9 assets

  • CASGEVYexa-cel / CASGEVY / BCL11A erythroid-specific enhancer / Non-viral ex vivo CRISPR/Cas9 gene-edited autologous cell therapy / Hemoglobinopathies
    Sickle cell disease, ages 5-11Regulatory submissions expected H1 2026Active pediatric expansionGlobalTransfusion-dependent beta thalassemia, ages 5-11Regulatory submissions expected H1 2026Active pediatric expansionGlobal
  • CTX310CTX310 / ANGPTL3 / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular/metabolic
    Severe hypertriglyceridemiaPhase 1bActive; update expected H2 2026Refractory hypercholesterolemiaPhase 1bActive; update expected H2 2026Heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias or severe hypertriglyceridemiaPhase 1Developed/being evaluated
  • CTX320CTX320 / LPA / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Elevated lipoprotein(a)Clinical trial / dose escalationActive; Lp(a) program update expected in 2026
  • CTX321CTX321 / LPA / Next-generation in vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Elevated lipoprotein(a)IND/CTA-enablingActive
  • CTX460CTX460 / SERPINA1 / In vivo SyNTase gene correction; LNP delivery / Rare disease
    Alpha-1 antitrypsin deficiencyPreclinical; clinical trial expected mid-2026Active
  • CTX340CTX340 / AGT / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Refractory hypertensionIND/CTA-enabling; clinical trial expected H1 2026Active
  • CTX611SRSD107 / Factor XI / FXI mRNA / Long-acting double-stranded siRNA / Thromboembolic/cardiovascular diseases
    Venous thromboembolism prevention after total knee arthroplastyPhase 2Ongoing; top-line data expected H2 2026EuropeAtrial fibrillation, venous thromboembolism, ischemic stroke, cancer-associated thrombosis, chronic kidney disease, peripheral vascular disease, chronic coronary artery diseaseTarget indications disclosed
  • Zugocabtagene geleucelzugo-cel; formerly CTX112 / CD19 / Allogeneic CAR-T cell therapy; CRISPR Cas9 engineered / Autoimmune disease; oncology
    Systemic lupus erythematosusPhase 1Ongoing; update expected H2 2026Systemic sclerosisPhase 1Ongoing; update expected H2 2026Inflammatory myositisPhase 1Ongoing; update expected H2 2026
  • CTX213CTX213 / iPSC-derived allogeneic gene-edited beta islet cell precursor therapy / Regenerative medicine / diabetes
    Type 1 diabetesPreclinical; progressing toward clinicActive

Latest news7 items

All news

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel

Presentation / Abstract • Phase 1Poster presentation Sun, Nov 8, 2026, 10:30 AM ET

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310 ® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean

Presentation / Abstract • Phase 1ESC Congress late-breaking presentation Fri, Aug 28, 2026

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni,

Presentation / Abstract • Phase 1ESC Congress presentation Fri, Aug 28, 2026, 4:30 PM CET

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3,

CRISPR Therapeutics AG - • Endpoint Arena